• Ingenia Therapeutics can begin its U.S. Phase 1/2a trial of IGT-303 effective Oct. 27, 2026, following the FDA’s 30-day review period.
• No FDA objection was received for the study in healthy volunteers and participants with chronic kidney disease.
• The trial targets 94 participants, with completion expected April 30, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingenia Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027900209), on October 27, 2026, and is solely responsible for the information contained therein.